Ywan Karlen, general manager EMEA, Ascentium Talent looks at why compliance-first AI training is the only kind European pharma will trust in 2026 — and what that means for L&D procurement.
Shutterstock - Quality Stock Arts
There is a particular kind of silence that settles over a procurement meeting when Medical or Legal walks in with questions the vendor cannot answer.
I witnessed this more than once during my years at Novartis. A training platform would arrive with an impressive demo: polished UI, enthusiastic account team, a pilot cohort that loved it. Commercial bought in. L&D bought in. And then someone sent the technical documentation to the MLR reviewers, or the security team ran their assessment, and the whole thing quietly disappeared. No announcement. No post-mortem. Just a shared drive folder that stopped receiving updates.
This is not an edge case. A recent pharmaphorum editorial argued persuasively that 2026 is less a breakthrough year for AI in pharma and more of a reckoning: one where governance, trust, and data provenance become the currency that matters. Having sat on both the commercial and technology sides of this industry, I would not disagree.
The demo is not the product
The challenge in pharma AI procurement is that the evaluation path is backwards. Most vendors lead with the user experience — and they should, because good UX is genuinely important. But in a regulated environment, user experience is the last question, not the first.
The first questions are: Can this system produce an auditable record of every interaction? Does it enforce fair-balance requirements, or can a representative inadvertently generate off-label messaging during a simulation? Where does the data reside, and under what legal framework? Can your Medical Governance team defend this system in front of a regulator?
Industry benchmarks from Indegene put MLR review cycles at 50 to 60 days per content piece in midand large-sized pharmaceutical companies under current workflows. An AI training platform that generates uncontrolled, non-audited content (even in a practice scenario) is not a productivity tool. It is a new source of review liability entering an already stretched system.
L&D leaders are often caught in the middle. They have genuine capability problems to solve and real pressure to deploy modern tools. But they are operating inside organisations where, in 2025 alone, the FDA issued over 200 enforcement letters challenging pharmaceutical advertising and promotion; the highest annual total in nearly 25 years, with 74 directed specifically at pharmaceutical and biologic manufacturers. The regulatory appetite for scrutiny is not softening, on the contrary.
The EU AI Act changes the structural calculation
European pharma is now navigating something more systemic than internal compliance culture. The EU AI Act entered into force on 1 August 2024 and becomes fully applicable on 2 August 2026, with prohibited AI practices and AI literacy obligations already in effect since 2 February 2025 and generalpurpose AI model obligations since 2 August 2025.
For AI systems that interact with field forces, simulate HCP conversations, and generate scored behavioural assessments, the implications are significant. High-risk AI obligations — including transparent documentation, human oversight, data governance, and lifecycle management — become fully enforceable from August 2026, with administrative fines of up to €35 million or 7% of global turnover for breaches of prohibited practices.
This is not theoretical future risk. A 2025 Pharmaceutical Technology survey found that approximately 60% of EU-based pharma companies plan to implement risk management systems for AI by 2027, and around 45% expect to overhaul their quality management systems for AI. Procurement and Legal teams are already conducting AI system inventories and gap analyses. Vendors that cannot provide conformity documentation, that cannot demonstrate their architecture was designed around these obligations, not retrofitted to meet them, are being removed from shortlists before a demo is ever scheduled.
The compliance gate has moved upstream. It is now a market entry condition.
What L&D buyers should be asking in 2026
The evaluation questions have changed. Based on what I have seen across both the buying and the vendor side of this industry, the conversations that lead to deployment — rather than the quiet disappearance of a shared drive folder — tend to start here:
Is this system MLR-aware by design, or by exception? There is a meaningful difference between a platform that enforces guardrails structurally and one that allows administrators to toggle restrictions on and off. The former survives governance review. The latter generates a risk memo.
Can every output be audited and attributed? A behavioural assessment that cannot produce a traceable record from simulation to scoring to feedback is not ready for a regulated environment, however compelling the aggregate results appear.
Where is the data, and who owns it? GDPR and Swiss FADP are not optional considerations for platforms operating in Europe. Regional data residency is a baseline requirement, not a premium feature.
Has the Medical Affairs team seen this, or only Commercial? If the answer is only Commercial, the evaluation is incomplete.
The compliance-first architecture is the filter, not the obstacle
The vendors most likely to survive European pharma procurement in 2026 are not necessarily those with the most sophisticated AI. They are those whose compliance architecture was built into the foundation, not added to satisfy a checklist.
One legal analysis from Clifford Chance frames it well: the AI Act does not replace existing legislation but adds to the matrix of overlapping regulations. Companies must now satisfy both vertical, industryspecific rules and the AI Act’s horizontal obligations simultaneously.
L&D leaders who understand this early gain a real advantage. Rather than cycling through pilots that fail at the governance stage, they can redirect evaluation effort toward the vendors designed to pass it. The compliance question is not a brake on AI adoption in pharma training. It is the mechanism that determines which tools actually get used.
The demos will keep getting better. The questions that kill them will stay the same.